Bioatla, INC. (BCAB) — SEC Filings

Q: What are the key financial highlights for Bioatla, INC.?

Key financial highlights for Bioatla, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Bioatla, INC.?

Key executives at Bioatla, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Bioatla, INC. stock?

Risk factors for Bioatla, INC. (BCAB) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Bioatla, INC.?

Forward-looking statements and predictions from Bioatla, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Bioatla, INC.. Recent 8-K filing on Mar 23, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.

View Bioatla, INC. on SEC EDGAR

Overview

Bioatla, INC. (BCAB) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Mar 23, 2026: BioAtla, Inc. filed an 8-K on March 23, 2026, reporting events from March 17, 2026, under Item 5.02 and Item 5.07. Item 5.02 covers changes in directors or officers and their compensation, while Item 5.07 relates to matters submitted to a security holder vote. This filing indicates potential signifi

Sentiment Summary

Across 39 filings, the sentiment breakdown is: 1 bullish, 6 bearish, 32 neutral. The dominant filing sentiment for Bioatla, INC. is neutral.

Filing Type Overview

Bioatla, INC. (BCAB) has filed 19 8-K, 2 DEF 14A, 6 10-Q, 2 10-K, 5 SC 13G/A, 3 SC 13D/A, 2 SC 13G with the SEC between Jan 2024 to Mar 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (39)

BioAtla 8-K: Officer/Director Changes & Shareholder Vote — 8-K · Mar 23, 2026
BioAtla, Inc. filed an 8-K on March 23, 2026, reporting events from March 17, 2026, under Item 5.02 and Item 5.07. Item 5.02 covers changes in directors or offi
BioAtla Files 8-K: Material Agreement, Equity Sales — 8-K · Dec 31, 2025 Risk: medium
BioAtla, Inc. filed an 8-K on December 31, 2025, reporting on events that occurred on December 30, 2025. The filing indicates an entry into a material definitiv
BioAtla Files 8-K for Shareholder Vote and Other Events — 8-K · Dec 30, 2025 Risk: low
BioAtla, Inc. filed an 8-K on December 30, 2025, to report on the submission of matters to a vote of security holders and other events. The filing does not cont
BioAtla Seeks Shareholder Nod for Equity Raise, Reverse Split to Avoid Delisting — DEF 14A · Dec 5, 2025 Risk: high
BioAtla, Inc. (BCAB) is holding a Special Meeting on December 30, 2025, to address critical financial and listing compliance issues. The company seeks stockhold
BioAtla Enters Material Definitive Agreement — 8-K · Nov 21, 2025 Risk: medium
On November 20, 2025, BioAtla, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company, incorporated in Delaware,
BioAtla's Cash Dries Up Amidst Zero Revenue, Going Concern Doubts — 10-Q · Nov 13, 2025 Risk: high
BioAtla, Inc. reported a significant decrease in cash and cash equivalents, falling from $49.046 million at December 31, 2024, to $8.320 million by September 30
BioAtla, Inc. Files 8-K Under 'Other Events' — 8-K · Sep 22, 2025 Risk: medium
BioAtla, Inc. filed an 8-K on September 22, 2025, reporting an event that occurred on September 16, 2025. The filing is categorized under 'Other Events' and doe
BioAtla Burns Cash on R&D, Reports $57.2M Net Loss in Q2 — 10-Q · Aug 7, 2025 Risk: high
BioAtla, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its clinical-stage status. The company incurred a net loss o
Bain Capital to Acquire BioAtla for $1.00/Share — 8-K · Jun 20, 2025 Risk: medium
BioAtla, Inc. announced on June 17, 2025, that it has entered into a definitive agreement to be acquired by an affiliate of Bain Capital Life Sciences for $1.00
BioAtla Faces Delisting Concerns — 8-K · May 16, 2025 Risk: high
BioAtla, Inc. filed an 8-K on May 16, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, with the earliest event
BioAtla, Inc. Q1 2025 10-Q Filing — 10-Q · May 6, 2025 Risk: medium
BioAtla, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported its financial position and operational activities, including details on
BioAtla Executive Compensation Details Revealed — DEF 14A · Apr 24, 2025 Risk: medium
BioAtla, Inc. filed a DEF 14A on April 24, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information
BioAtla Files 2024 10-K, Details BeiGene Deal — 10-K · Mar 28, 2025 Risk: medium
BioAtla, Inc. filed its 10-K for the fiscal year ending December 31, 2024, reporting on its operations and financial condition. The company's business address i
BioAtla, Inc. Files 8-K Report — 8-K · Mar 27, 2025 Risk: low
On March 27, 2025, BioAtla, Inc. filed an 8-K report detailing financial results and other material information. The filing indicates the company's principal ex
BioAtla Appoints New CEO, CMO, and Directors — 8-K · Mar 14, 2025 Risk: medium
BioAtla, Inc. announced on March 11, 2025, changes in its executive and director roles. Dr. Jay L. Short has been appointed as Chief Executive Officer and Presi
BioAtla Faces Delisting Concerns — 8-K · Feb 7, 2025 Risk: high
BioAtla, Inc. filed an 8-K on February 7, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, effective February 6
BioAtla Files 8-K for Reg FD and Financials — 8-K · Dec 20, 2024 Risk: low
BioAtla, Inc. filed an 8-K on December 20, 2024, to report information under Regulation FD and to file financial statements and exhibits. The filing details the
SC 13G/A Filing — SC 13G/A · Nov 14, 2024
BioAtla Files Q3 2024 10-Q, Details R&D and Collaborations — 10-Q · Nov 7, 2024 Risk: medium
BioAtla, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported research and development expenses for the nine months ended Septembe
Soleus Private Equity Amends BioAtla Stake — SC 13D/A · Oct 2, 2024 Risk: medium
Soleus Private Equity GP I, LLC, along with its affiliates, has amended its Schedule 13D filing for BioAtla, Inc. on October 2, 2024. This amendment reflects ch
BioAtla Files 8-K for Material Agreement — 8-K · Sep 23, 2024 Risk: medium
On September 23, 2024, BioAtla, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes financial statements and exhibits r
Soleus Private Equity Ups Stake in BioAtla to 10.1% — SC 13D/A · Sep 6, 2024 Risk: medium
Soleus Private Equity GP I, LLC, along with its affiliates, has amended its Schedule 13D filing for BioAtla, Inc. on September 6, 2024. The filing indicates a c
BioAtla Files Q2 2024 10-Q, Details Financials — 10-Q · Aug 8, 2024 Risk: medium
BioAtla, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates. Key financial data points in
SC 13G Filing — SC 13G · Aug 7, 2024
SC 13G/A Filing — SC 13G/A · Jul 8, 2024
BioAtla, Inc. Reports on Shareholder Vote Matters — 8-K · Jun 13, 2024 Risk: low
BioAtla, Inc. filed an 8-K on June 13, 2024, to report on the submission of matters to a vote of its security holders. The filing does not contain details about
BioAtla Files 8-K: Other Events — 8-K · May 17, 2024 Risk: low
BioAtla, Inc. filed an 8-K on May 17, 2024, reporting an event that occurred on May 15, 2024. The filing is categorized under 'Other Events' and does not specif
BioAtla, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 14, 2024 Risk: low
BioAtla, Inc. (BCAB) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. BioAtla, Inc. filed a 10-Q report for the period ending March 31, 2024. The f
BioAtla Files 8-K with Bylaw Amendments and Exhibits — 8-K · Apr 24, 2024 Risk: low
On April 22, 2024, BioAtla, Inc. filed an 8-K report detailing amendments to its articles of incorporation and bylaws. The filing also included financial statem
Soleus Private Equity Amends BioAtla Stake — SC 13D/A · Apr 16, 2024 Risk: medium
Soleus Private Equity GP I, LLC, along with its affiliates, has amended its Schedule 13D filing for BioAtla, Inc. on April 16, 2024. The filing indicates a chan
BioAtla, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 26, 2024 Risk: medium
BioAtla, Inc. (BCAB) filed a Annual Report (10-K) with the SEC on March 26, 2024. BioAtla, Inc. filed its 2023 Form 10-K on March 26, 2024, reporting on its fis
BioAtla Reports Executive Changes and Compensation Arrangements — 8-K · Feb 21, 2024 Risk: medium
BioAtla, Inc. filed an 8-K on February 21, 2024, reporting an event that occurred on February 15, 2024. The filing pertains to Item 5.02, which covers the depar
SC 13G/A Filing — SC 13G/A · Feb 14, 2024
BioAtla (BCAB) Files Routine 8-K for 'Other Event' — 8-K · Feb 12, 2024 Risk: low
BioAtla, Inc. (BCAB) filed an 8-K on February 12, 2024, reporting an 'Other Event' that occurred on February 6, 2024. This filing is a routine disclosure indica
BioAtla Insider Jay Short Holds 2.1M Shares, 405K Options — SC 13G/A · Feb 9, 2024 Risk: low
Dr. Jay M. Short, a key figure at BioAtla, Inc., filed an amendment to his Schedule 13G, revealing he beneficially owns 2,103,542 shares of the company's common
Acorn Bioventures Cuts BioAtla Stake to 4.9% — SC 13G/A · Feb 6, 2024
Acorn Bioventures, L.P. filed an amended SC 13G/A on February 6, 2024, disclosing its beneficial ownership in BioAtla, Inc. (NASDAQ: BCAB) as of December 31, 20
BlackRock Discloses 5.1% Passive Stake in BioAtla — SC 13G · Jan 29, 2024
BlackRock, Inc. reported on January 29, 2024, that as of December 31, 2023, it beneficially owned 3,369,825 shares of BioAtla, Inc.'s common stock, representing
BioAtla Files 8-K for Regulation FD Disclosure, Exhibits — 8-K · Jan 9, 2024
BioAtla, Inc. filed an 8-K on January 9, 2024, to disclose information under Regulation FD and to include financial statements and exhibits. This filing, under
BioAtla (BCAB) Announces 1-for-20 Reverse Stock Split — 8-K · Jan 8, 2024
On January 5, 2024, BioAtla, Inc. (BCAB) filed an 8-K to report amendments to its Certificate of Incorporation, specifically implementing a reverse stock split

Risk Profile

Risk Assessment: Of BCAB's 30 recent filings, 5 were flagged as high-risk, 16 as medium-risk, and 9 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Bioatla, INC.'s most recent 10-Q filing (Nov 13, 2025):

Revenue: $0
Net Income: -$15.778M
EPS: N/A
Debt-to-Equity: N/A
Cash Position: $8.320M
Operating Margin: N/A
Total Assets: $15.908M
Total Debt: $47.145M

Key Executives

Jay M. Short, Ph.D.
San Diego, California
Dr. Jay L. Short
Dr. Scott R. Burger
Guy Levy
Jay M. Short

Industry Context

BioAtla operates in the biotechnology sector, a highly competitive and capital-intensive industry. Companies in this space often face challenges in securing funding for research and development, and maintaining compliance with exchange listing requirements. The sector is characterized by long development cycles, high failure rates, and significant regulatory hurdles, making consistent access to capital crucial for survival and growth.

Top Tags

corporate-governance (5) · Biotechnology (4) · 10-Q (4) · financials (4) · shareholder-vote (3) · R&D Expenses (3) · sec-filing (3) · amendment (3) · material-agreement (2) · regulation-fd (2)

Key Numbers

Threshold for common stock issuance requiring stockholder approval: 20% — Nasdaq Listing Rule 5635(d) threshold for issuances below market price
Exchange Cap shares: 11,752,538 shares — 19.99% of outstanding common stock as of November 20, 2025, without stockholder approval
Reverse Stock Split ratio range: 1-for-5 to 1-for-20 — Discretionary range for the board to increase per share market price
Minimum Bid Price Requirement: $1.00 — Nasdaq Listing Rule 5450(a)(1) threshold for continued listing
Special Meeting Date: December 30, 2025 — Date stockholders will vote on proposals
Nasdaq Compliance Deadline: February 2, 2026 — Deadline to demonstrate compliance with Minimum Bid Price Requirement
Minimum Stockholders' Equity Requirement Deadline: December 31, 2025 — Deadline to demonstrate compliance with Nasdaq Listing Rule 5450(b)(1)(A)
Common Stock outstanding: 59,035,516 shares — As of November 25, 2025, Record Date
Payment premium: 10% — Required if Pre-Paid Advances cannot be converted to stock and must be repaid in cash
Commission File Number: 001-39787 — SEC File Number for BioAtla, Inc.
IRS Employer Identification No.: 85-1922320 — EIN for BioAtla, Inc.
Cash and cash equivalents: $8.320M — Decreased from $49.046 million at Dec 31, 2024, an 83% decline.
Collaboration and other revenue: $0 — For three and nine months ended Sep 30, 2025, down from $11.000 million in 2024.
Net loss (Q3 2025): $15.778M — Widened from $10.586 million in Q3 2024.
Net loss (9 months 2025): $49.823M — Compared to $54.892 million in 9 months 2024.

Forward-Looking Statements

{"claim":"Dr. Jay M. Short will maintain a significant ownership stake in BioAtla, Inc. for the foreseeable future.","entity":"Jay M. Short","targetDate":"December 31, 2024","confidence":"medium"}

Related Companies

BioAtla, Inc. · ATLA

Frequently Asked Questions

What are the latest SEC filings for Bioatla, INC. (BCAB)?

Bioatla, INC. has 39 recent SEC filings from Jan 2024 to Mar 2026, including 19 8-K, 6 10-Q, 5 SC 13G/A. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of BCAB filings?

Across 39 filings, the sentiment breakdown is: 1 bullish, 6 bearish, 32 neutral. The dominant sentiment is neutral.

Where can I find Bioatla, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Bioatla, INC. (BCAB) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Bioatla, INC.?

Key financial highlights from Bioatla, INC.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for BCAB?

The investment thesis for BCAB includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Bioatla, INC.?

Key executives identified across Bioatla, INC.'s filings include Jay M. Short, Ph.D., San Diego, California, Dr. Jay L. Short, Dr. Scott R. Burger, Guy Levy and 1 others.

What are the main risk factors for Bioatla, INC. stock?

Of BCAB's 30 assessed filings, 5 were flagged high-risk, 16 medium-risk, and 9 low-risk.

What are recent predictions and forward guidance from Bioatla, INC.?

Recent forward-looking statements from Bioatla, INC. include guidance on {"claim":"Dr. Jay M. Short will maintain a significant ownership stake in BioAtla, Inc. for the foreseeable future.","en.